Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06419751
Other study ID # 2023-ZX067
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 30, 2024
Est. completion date June 30, 2025

Study information

Verified date May 2024
Source China National Center for Cardiovascular Diseases
Contact Yifan Wu
Phone 01088398069
Email wuyifan1127@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To explore the effect of smart app and wearable-based lifestyle intervention management on vascular health, comparing different exercise with the improvement of vascular arterial stiffness. The accuracy and consistency evaluation of smart wearable devices in screening for vascular health risks were also discussed.


Description:

This study intends to carry out a randomized controlled trial to dynamically monitor a variety of cardiovascular parameters in people with high risk of vascular health, using wearable devices and artificial intelligence-assisted health management platform, and provide intelligent lifestyle intervention programs with different exercise.By observing the improvement of vascular health in the study population, the management effect of intelligent lifestyle intervention on high-risk groups of vascular health was evaluated. It is expected that through comprehensive lifestyle intervention based on smart wearable devices, early prevention and control of arteriosclerosis can be achieved, the level of hospital health management will be improved, and more physical health and health economic benefits will be obtained.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 216
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Age: = 18 years old and < 60 years old; 2. cfPWV>10m/s; 3. Those who have 1 intelligent communication device and can use it proficiently (Android mobile phone is preferred); 4. People who have lived and/or worked relatively steadily in the past 6 months; 5. Signed informed consent. Exclusion Criteria: 1. Moderate to severe obesity (=30kg/m^2); 2. Acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic stenosis and other serious circulatory respiratory diseases and acute cardiovascular and cerebrovascular diseases; 3. severe essential hypertension (systolic blood pressure =180mmHg and/or diastolic blood pressure =110mmHg) or poorly controlled essential hypertension; 4. Patients with secondary hypertension, acute hypertension, subacute hypertension and hypertensive encephalopathy; 5. Significant arrhythmia (atrial fibrillation, etc.); 6. Patients with atherosclerotic cardiovascular diseases, such as coronary heart disease, severe peripheral atherosclerotic diseases, etc.; 7. Type 1 diabetes, uncontrolled type 2 diabetes or other diseases affecting carbohydrate metabolism; 8. Severe stenosis of the carotid and/or femoral arteries (resulting in significant abnormalities in the blood flow spectrum); Those who have anatomical abnormalities of the aorta and major branches and cannot complete PWV detection; 9. Cancer and other major comorbidities affecting arterial blood pressure; 10. Those who are unable to exercise due to fractures, joint instability and other physical diseases or diseases affecting the locomotor system; 11. Those who have involuntary physical movements due to mental illness, epilepsy or other diseases; 12. Those who have a pacemaker installed; 13. Pregnant/trying to conceive; 14. Patients with allergies, limb trauma or skin diseases who cannot cooperate with the completion of ABI and baPWV index examinations; 15. Those who have undergone or plan to have bariatric surgery in the next 12 months; 16. Those who have participated in other clinical studies in the past 3 months; 17. Refusal to sign informed consent.

Study Design


Intervention

Behavioral:
Regular exercise
Based on the study participant's status and exercise assessment, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the same time, choose non-consecutive 3 days of resistance training in 5 aerobic training sessions to increase resistance training (choose 1~2 muscle groups each time, 4~5 movements, repeat each action 8~12 times, repeat 2~3 sets)
Baduanjin
A professional therapist instructed the participants to learn and train Baduanjin before the intervention, and a standardized Baduanjin exercise program included eight postures, each training time was about 50 minutes (including 10 min of warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
China National Center for Cardiovascular Diseases

Outcome

Type Measure Description Time frame Safety issue
Primary Cervical femoral pulse wave velocity(cfPWV) The cardio-cerebrovascular and aortic function detector (Campura, France, model: Complior Analyse) was used to measure cfPWV, and the study participants were in a supine position, lying flat on the pillow, with their palms up on their sides of the body, so that their whole body was relaxed and rested for about 3 minutes. PWV can reflect arterial stiffness, and the European Society of Cardiology recommends cfPWV >10 m/s as the definitive threshold for assessing arterial functional changes in hypertension.We monitored cfPWV at baseline,3,6,9 months of the study. baseline,3months,6months,9 months
Secondary Brachi-ankle pulse wave velocity(baPWV) The blood pressure of the limbs is measured with the Omron arteriosclerosis detector, and the pulse conduction velocity (baPWV) and ankle-brachial index (ABI) are calculated to automatically evaluate the degree of arteriosclerosis and blood vessel blockage. Positive criteria for baPWV: =1400 cm/s or baPWV% = 19% is arteriosclerosis. Lower extremity vascular occlusion (ABI positive criteria): =0.9 for peripheral arterial stenosis and =0.5 for possible peripheral arterial occlusion.We monitored baPWV at baseline,3,6,9 months of the study. baseline,3months,6months,9 months
Secondary blood pressure Blood pressure indicator: systolic blood pressure and diastolic blood pressure.We monitored blood pressure at baseline,3,6,9 months of the study. baseline,3months,6months,9 months
Secondary body weight Using bioelectrical impedance analysis to monitor body weight,weight and height will be combined to report BMI in kg/m^2.We monitored body composition at baseline,3,6,9 months of the study. baseline,3months,6months,9 months
Secondary Lipid metabolism parameters: TC(mmol/L), TG(mmol/L), HDL-C(mmol/L), LDL-C(mmol/L) Lipid metabolism indicators: total cholesterol , triglyceride , high density lipoprotein cholesterol, low density lipoprotein cholesterol.We monitored lipid metabolism parameters at baseline,3,6,9 months of the study. baseline,3months,6months,9 months
Secondary Physical fitness The measurement of muscle strength, balance and flexibility is completed by the rehabilitation therapist, mainly including: (1) upper limb muscle strength test (dumbbell arm curl test); (2) Lower limb muscle strength test (chair standing and sitting test); (3) balance ability test; (4) Lower limb flexibility assessment (chair sitting body forward bending test); (5) Upper limb flexibility assessment (two-hand dorsum extension test). Participants were observed for changes at baseline, 3,6,9 months. baseline,3months,6months,9 months
Secondary Vascular Health Index The PWV was analyzed by the smart watch through ECG (electrocardiogram) and PPG (photoplethysmography) sensors to evaluate the degree of vascular elasticity, and the vascular health index and evaluation were obtained, and the results were divided into low-risk, medium-risk, and high-risk. baseline,3months,6months,9 months
Secondary Application adherence Study participants who received remote lifestyle interventions through the app, completed all exercise training content per week, or clocked in = exercise 3 times were considered to have good compliance; Those who check in < exercise 3 times a week are considered to have poor compliance. baseline,3months,6months,9 months
See also
  Status Clinical Trial Phase
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Active, not recruiting NCT05773287 - Targeted Health Coaching to Improve Physical Activity Post-Structured Cardiac Rehabilitation N/A
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Completed NCT02542163 - Pilot Evaluation of the NimbleHeart Harness System in Cardiac Rehabilitation (PEN-CR) N/A
Not yet recruiting NCT05989594 - Home-based Mobile Guided Exercise-based Cardiac Rehabilitation Among Patients Undergoing TAVR N/A
Active, not recruiting NCT05026957 - A Digitally-Supported Shared Decision Making Approach for Coronary Artery Disease Patients During Cardiac Rehabilitation N/A
Recruiting NCT03734185 - Cardiac Rehabilitation: From Hospital to Municipal Setting. N/A
Recruiting NCT05826587 - Cardiac Rehabilitation Mobile-Health Fall Risk Prevention Intervention N/A
Completed NCT03174106 - Longterm Follow-up of Cardiac Patients With an Smartphone-Application N/A
Recruiting NCT05725655 - Hot Water Immersion After Myocardial Infarction N/A
Not yet recruiting NCT05019157 - Cardiac Telerehabilitation Effectiveness Using Wearable Sensors N/A
Recruiting NCT06025526 - Effectiveness of the Aktivplan Digital Intervention (ACTIVE-CaRe Pilot) N/A
Recruiting NCT05099692 - CHD Patient's Concern on Cardiac Rehabilitation
Completed NCT06306235 - Are Non-participants of Conventional Centre-based Cardiac Rehabilitation Willing to Participate in Cardiac Telerehabilitation?
Recruiting NCT06039969 - Evaluate Aerobic Exercise on Myocardial Fibrosis and Intestinal Flora in Dilated Cardiomyopathy Diagnosed First Time.
Not yet recruiting NCT06065319 - Wearables and Cardiac Rehabilitation
Recruiting NCT06127537 - Study on the Efficacy of HE and Therapeutic Group Factors on CR and QoL N/A
Completed NCT04738383 - Feasibility and Acceptance of Changes in Medical Supervision of Exercise Groups in Cardiac Rehabilitation N/A
Active, not recruiting NCT03922529 - Modified Application of Cardiac Rehabilitation for Older Adults N/A
Completed NCT00956657 - Improving Cardiac Rehabilitation Session Attendance: A Randomised Controlled Trial N/A